Angiomax in Patients With HIT/HITTS Type II Undergoing CPB
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate that in patients with heparin-induced
thrombocytopenia (HIT)/heparin-induced thrombocytopenia and thrombosis syndrome (HITTS) Type
II undergoing cardiac surgery on cardiopulmonary bypass (CPB), Angiomax is a safe and
effective anticoagulant.